Study of SYS6055 for aggressive B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new injection called SYS6055 for people with an aggressive form of B-cell lymphoma that has stopped responding to or returned after standard treatments. The goal is to see if this therapy can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have given written consent to participate.
- You have been diagnosed with a fast-growing type of B-cell lymphoma that has come back or did not respond to standard treatment.
- Your lymphoma cells have a protein called CD19, and you have at least one tumor that can be seen on a scan.
- You are in fairly good health (able to do your daily activities without help) and expected to live at least 3 months.
- Your organs (like liver, kidneys, and bone marrow) are working well enough.
- If you could become pregnant or father a child, you agree to use effective birth control for 1 year after the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SYS6055 for people with B-cell cancers (leukemia or lymphoma) that have not improved or have come back after standard treatments. It aims to see if the drug is safe and effective.
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This Phase 1 study tests whether a new drug called SYS6051 is safe and effective for people with advanced solid tumors (cancer that has spread). Researchers will evaluate how well your body tolerates the drug and monitor for side effects.
This trial tests a new drug called TRS005 for people with a specific type of lymphoma (CD20-positive DLBCL) that has come back or not responded to at least two prior treatments. It is for those who cannot have a stem cell transplant and aims to see if the drug can shrink tumors and help control the disease.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
Hear when a new Relapsed/Refractory Aggressive B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.